A midstage trial assessing the chimeric antigen receptor T-cell therapy idecabtagene vicleucel, developed by bluebird bio and Bristol Myers Squibb, found adults older than 65 with relapsed or refractory multiple myeloma had higher response rates than the overall study group. The findings were presented at the Transplantation & Cellular Therapy Meetings.
CAR T-cell therapy response rate higher among older adults
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.